Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 681678, 14 pages
http://dx.doi.org/10.1155/2014/681678
Review Article

B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers

Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico San Matteo Foundation/University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy

Received 12 January 2014; Accepted 4 March 2014; Published 29 April 2014

Academic Editor: Gabriel J. Tobón

Copyright © 2014 Serena Bugatti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. G. Kunkel and R. C. Williams, “Rheumatoid arthritis,” Annual Review of Medicine, vol. 15, pp. 37–52, 1964. View at Google Scholar · View at Scopus
  2. M. Feldmann, F. M. Brennan, and R. N. Maini, “Rheumatoid arthritis,” Cell, vol. 85, no. 3, pp. 307–310, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. W. Edwards, M. J. Leandro, and G. Cambridge, “B lymphocyte depletion therapy with rituximab in rheumatoid arthritis,” Rheumatic Disease Clinics of North America, vol. 30, no. 2, pp. 393–403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Caporali, M. Caprioli, F. Bobbio-Pallavicini, S. Bugatti, and C. Montecucco, “Long term treatment of rheumatoid arthritis with rituximab,” Autoimmunity Reviews, vol. 8, no. 7, pp. 591–594, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. G. J. Tobón, J. H. Izquierdo, and C. A. Cañas, “B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus,” Autoimmune Diseases, vol. 2013, Article ID 827254, 17 pages, 2013. View at Publisher · View at Google Scholar
  6. S. Bugatti, V. Codullo, R. Caporali, and C. Montecucco, “B cells in rheumatoid arthritis,” Autoimmunity Reviews, vol. 7, no. 2, pp. 137–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Blüml, K. McKeever, R. Ettinger, J. Smolen, and R. Herbst, “B-cell targeted therapeutics in clinical development,” Arthritis Research & Therapy, vol. 15, supplement 1, article S4, 2013. View at Google Scholar
  8. H. Wardemann, S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig, “Predominant autoantibody production by early human B cell precursors,” Science, vol. 301, no. 5638, pp. 1374–1377, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Samuels, Y.-S. Ng, C. Coupillaud, D. Paget, and E. Meffre, “Impaired early B cell tolerance in patients with rheumatoid arthritis,” Journal of Experimental Medicine, vol. 201, no. 10, pp. 1659–1667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Meffre, “The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases,” Annals of the New York Academy of Sciences, vol. 1246, no. 1, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Menard, J. Samuels, Y.-S. Ng, and E. Meffre, “Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 63, no. 5, pp. 1237–1245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. R. Ehrenstein, J. G. Evans, A. Singh et al., “Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy,” Journal of Experimental Medicine, vol. 200, no. 3, pp. 277–285, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Rapetti, K. M. Chavele, C. M. Evans, and M. R. Ehrenstein, “B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis,” Annals of the Rheumatic Diseases, 2013. View at Publisher · View at Google Scholar
  14. G. S. Cheema, V. Roschke, D. M. Hilbert, and W. Stohl, “Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases,” Arthritis and Rheumatism, vol. 44, no. 6, pp. 1313–1319, 2001. View at Google Scholar
  15. S. Bosello, P. Youinou, C. Daridon et al., “Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis,” Journal of Rheumatology, vol. 35, no. 7, pp. 1256–1264, 2008. View at Google Scholar · View at Scopus
  16. T. M. Seyler, Y. W. Park, S. Takemura et al., “BLyS and APRIL in rheumatoid arthritis,” Journal of Clinical Investigation, vol. 115, no. 11, pp. 3083–3092, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. Moura, R. Cascão, I. Perpétuo et al., “Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival,” Rheumatology, vol. 50, no. 2, pp. 278–282, 2011. View at Google Scholar
  18. F. MacKay and P. Schneider, “Cracking the BAFF code,” Nature Reviews Immunology, vol. 9, no. 7, pp. 491–502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Bombardieri, N.-W. Kam, F. Brentano et al., “A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells,” Annals of the Rheumatic Diseases, vol. 70, no. 10, pp. 1857–1865, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Alsaleh, A. François, A.-M. Knapp et al., “Synovial fibroblasts promote immunoglobulin class switching by a mechanism involving BAFF,” European Journal of Immunology, vol. 41, no. 7, pp. 2113–2122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. Sweet, M. L. Ols, J. L. Cullen, A. V. Milam, H. Yagita, and M. J. Shlomchik, “Facultative role for T cells in extrafollicular Toll-like receptor-dependent autoreactive B-cell responses in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 19, pp. 7932–7937, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. R. A. Herlands, S. R. Christensen, R. A. Sweet, U. Hershberg, and M. J. Shlomchik, “T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells,” Immunity, vol. 29, no. 2, pp. 249–260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. M. Haberman, J. William, C. Euler, and M. J. Shlomchik, “Rheumatoid factors in health and disease: structure, function, induction and regulation,” Current Directions in Autoimmunity, vol. 6, pp. 169–195, 2003. View at Google Scholar · View at Scopus
  24. K. Lundberg, C. Bengtsson, N. Kharlamova et al., “Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile,” Annals of the Rheumatic Diseases, vol. 72, no. 5, pp. 652–658, 2013. View at Google Scholar
  25. K. Amara, J. Steen, E. Murray et al., “Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition,” Journal of Experimental Medicine, vol. 210, no. 3, pp. 445–455, 2013. View at Google Scholar
  26. F. Bobbio-Pallavicini, C. Alpini, R. Caporali, S. Avalle, S. Bugatti, and C. Montecucco, “Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment,” Arthritis Research & Therapy, vol. 6, no. 3, pp. R264–272, 2004. View at Google Scholar · View at Scopus
  27. F. Bobbio-Pallavicini, R. Caporali, S. Bugatti, and C. Montecucco, “What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies?” Journal of Rheumatology, vol. 35, no. 10, pp. 1903–1905, 2008. View at Google Scholar · View at Scopus
  28. A. Lanzavechia, “Antigen uptake and accumulation in antigen-specific B cells,” Immunological Reviews, no. 99, pp. 39–51, 1987. View at Google Scholar · View at Scopus
  29. E. A. Leadbetter, I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein, “Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors,” Nature, vol. 416, no. 6881, pp. 603–607, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Takemura, P. A. Klimiuk, A. Braun, J. J. Goronzy, and C. M. Weyand, “T cell activation in rheumatoid synovium is B cell dependent,” Journal of Immunology, vol. 167, no. 8, pp. 4710–4718, 2001. View at Google Scholar · View at Scopus
  31. D. Makrygiannakis, E. Af Klint, I. E. Lundberg et al., “Citrullination is an inflammation-dependent process,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1219–1222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. T. A. Barr, P. Shen, S. Brown et al., “B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cell,” Journal of Experimental Medicine, vol. 209, no. 5, pp. 1001–1010, 2012. View at Google Scholar
  33. L. Yeo, K.-M. Toellner, M. Salmon et al., “Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 11, pp. 2022–2028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. P. K. K. Wong, J. M. W. Quinn, N. A. Sims, A. Van Nieuwenhuijze, I. K. Campbell, and I. P. Wicks, “Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 158–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Thiolat, L. Semerano, Y. M. Pers et al., “Interleukin-6 receptor blockade enhances CD39+ regulatory T cell sevelopment in rheumatoid arthritis and in experimental arthritis,” Arthritis and Rheumatology, vol. 66, no. 2, pp. 273–283, 2014. View at Google Scholar
  36. A. Kimura and T. Kishimoto, “IL-6: regulator of Treg/Th17 balance,” European Journal of Immunology, vol. 40, no. 7, pp. 1830–1835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Mitsdoerffer, Y. Lee, A. Jäger et al., “Proinflammatory T helper type 17 cells are effective B-cell helpers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 32, pp. 14292–14297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. F. L. van de Veerdonk, B. Lauwerys, R. J. Marijnissen et al., “The anti-CD20 antibody rituximab reduces the Th17 cell response,” Arthritis and Rheumatism, vol. 63, no. 6, pp. 1507–1516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. P. M. Schlegel, I. Steiert, I. Kötter, and C. A. Müller, “B cells contribute to heterogeneity of IL-17 producing cells in rheumatoid arthritis and healthy controls,” PLoS ONE, vol. 8, no. 12, Article ID e82580, 2013. View at Publisher · View at Google Scholar
  40. S. Frey, A. Derer, M. E. Messbacher et al., “The novel cytokine interleukin-36a is expressed in psoriatic and rheumatoid arthritis synovium,” Annals of the Rheumatic Diseases, vol. 72, no. 9, pp. 1569–1574, 2013. View at Google Scholar
  41. P. A. Blair, L. Y. Noreña, F. Flores-Borja et al., “CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients,” Immunity, vol. 32, no. 1, pp. 129–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Flores-Borja, A. Bosma, D. Ng et al., “CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation,” Science Translational Medicine, vol. 5, no. 173, Article ID 173ra23, 2013. View at Publisher · View at Google Scholar
  43. S. Lemoine, A. Morva, P. Youinou, and C. Jamin, “Human T cells induce their own regulation through activation of B cells,” Journal of Autoimmunity, vol. 36, no. 3-4, pp. 228–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Ma, B. Liu, Z. Jiang, and Y. Jiang, “Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis,” Clinical Rheumatology, vol. 33, no. 2, pp. 187–195, 2014. View at Google Scholar
  45. G. Schett and E. Gravallese, “Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment,” Nature Reviews Rheumatology, vol. 8, no. 11, pp. 656–664, 2012. View at Google Scholar
  46. U. Harre, D. Georgess, H. Bang et al., “Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin,” Journal of Clinical Investigation, vol. 122, no. 5, pp. 1791–1802, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Kocijan, S. Finzel, M. Englbrech, K. Engelke, J. Rech, and G. Schett, “Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity,” Annals of the Rheumatic Diseases, 2013. View at Publisher · View at Google Scholar
  48. A. Kleyer, S. Finzel, J. Rech et al., “Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies,” Annals of the Rheumatic Diseases, 2013. View at Publisher · View at Google Scholar
  49. H. Kokkonen, I. Söderström, J. Rocklöv, G. Hallmans, K. Lejon, and S. Rantapää Dahlqvist, “Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 62, no. 2, pp. 383–391, 2010. View at Google Scholar
  50. Y. Rombouts, E. Ewing, L. A. van de Stadt et al., “Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis,” Annals of the Rheumatic Diseases, 2013. View at Publisher · View at Google Scholar
  51. E. Jimenez-Boj, K. Redlich, B. Türk et al., “Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis,” Journal of Immunology, vol. 175, no. 4, pp. 2579–2588, 2005. View at Google Scholar · View at Scopus
  52. S. Finzel, J. Rech, S. Schmidt et al., “Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion,” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1587–1593, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. R. A. Moura, P. Weinmann, P. A. Pereira et al., “Alterations on peripheral blood B-cell subpopulations in very early arthritis patients,” Rheumatology, vol. 49, no. 6, pp. 1082–1092, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Wang, Y. Shan, Z. Jiang et al., “High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis,” Clinical & Experimental Immunology, vol. 174, no. 2, pp. 212–220, 2013. View at Google Scholar
  55. M. M. Souto-Carneiro, V. Mahadevan, K. Takada et al., “Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor,” Arthritis Research and Therapy, vol. 11, no. 3, article R84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Sellam, S. Rouanet, H. Hendel-Chavez et al., “Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 63, no. 12, pp. 3692–3701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J. H. Anolik, R. Ravikumar, J. Barnard et al., “Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks,” Journal of Immunology, vol. 180, no. 2, pp. 688–692, 2008. View at Google Scholar · View at Scopus
  58. T. Nanki, K. Takada, Y. Komano et al., “Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis,” Arthritis Research and Therapy, vol. 11, no. 5, article R149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Sellam, S. Rouanet, H. Hendel-Chavez et al., “CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 65, no. 9, pp. 2253–2261, 2013. View at Google Scholar
  60. S. Bugatti, A. Manzo, M. Bombardieri et al., “Synovial tissue heterogeneity and peripheral blood biomarkers,” Current Rheumatology Reports, vol. 13, no. 5, pp. 440–448, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. C. A. Scirè, O. Epis, V. Codullo et al., “Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure,” Arthritis Research and Therapy, vol. 9, no. 5, article 101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Manzo, M. Bombardieri, F. Humby, and C. Pitzalis, “Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling,” Immunological Reviews, vol. 233, no. 1, pp. 267–285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Takemura, A. Braun, C. Crowson et al., “Lymphoid neogenesis in rheumatoid synovitis,” Journal of Immunology, vol. 167, no. 2, pp. 1072–1080, 2001. View at Google Scholar · View at Scopus
  64. A. Manzo, S. Paoletti, M. Carulli et al., “Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis,” European Journal of Immunology, vol. 35, no. 5, pp. 1347–1359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Manzo, S. Bugatti, R. Caporali et al., “CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis,” American Journal of Pathology, vol. 171, no. 5, pp. 1549–1562, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Humby, M. Bombardieri, A. Manzo et al., “Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium,” PLoS Medicine, vol. 6, no. 1, article e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. H.-J. Kim, V. Krenn, G. Steinhauser, and C. Berek, “Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis,” Journal of Immunology, vol. 162, no. 5, pp. 3053–3062, 1999. View at Google Scholar · View at Scopus
  68. T. Scheel, A. Gursche, J. Zacher, and C. Berek, “V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 63–72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Kuca-Warnawin, T. Burakowski, W. Kurowska et al., “Elevated number of recently activated T cells in bone marrow of patients with rheumatoid arthritis: a role for interleukin 15?” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 227–233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Engels, S. Oeschger, M.-L. Hansmann, M. Hillebrand, and S. Kriener, “Bone marrow trephines containing lymphoid aggregates from patients with rheumatoid and other autoimmune disorders frequently show clonal B-cell infiltrates,” Human Pathology, vol. 38, no. 9, pp. 1402–1411, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Bugatti, A. Manzo, R. Caporali, and C. Montecucco, “Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective,” Arthritis Research & Therapy, vol. 14, no. 6, article 229, 2012. View at Google Scholar
  72. S. Bugatti, R. Caporali, A. Manzo, B. Vitolo, C. Pitzalis, and C. Montecucco, “Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment,” Arthritis and Rheumatism, vol. 52, no. 11, pp. 3448–3459, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Dalbeth, T. Smith, S. Gray et al., “Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease,” Annals of the Rheumatic Diseases, vol. 68, no. 2, pp. 279–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Duer-Jensen, K. Hoørslev-Petersen, M. L. Hetland et al., “Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis,” Arthritis and Rheumatism, vol. 63, no. 8, pp. 2192–2202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Bugatti, R. Caporali, A. Manzo, G. Sakellariou, S. Rossi, and C. Montecucco, “Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 625–626, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. E. A. Haavardsholm, P. Bøyesen, M. Østergaard, A. Schildvold, and T. K. Kvien, “Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression,” Annals of the Rheumatic Diseases, vol. 67, no. 6, pp. 794–800, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Rodríguez-Palmero, C. Pelegrí, M. J. Ferri, M. Castell, À. Franch, and C. Castellote, “Alterations of lymphocyte populations in lymph nodes but not in spleen during the latency period of adjuvant arthritis,” Inflammation, vol. 23, no. 2, pp. 153–165, 1999. View at Google Scholar · View at Scopus
  78. L. Mandik-Nayak, B. T. Wipke, F. F. Shih, E. R. Unanue, and P. M. Allen, “Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14368–14373, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. S. T. Proulx, E. Kwok, Z. You et al., “MRI and quantification of draining lymph node function in inflammatory arthritis,” Annals of the New York Academy of Sciences, vol. 1117, pp. 106–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. S. T. Proulx, E. Kwok, Z. You et al., “Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography,” Arthritis and Rheumatism, vol. 56, no. 12, pp. 4024–4037, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Li, I. Kuzin, S. Moshkani et al., “Expanded CD23+/CD21hi B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy,” Journal of Immunology, vol. 184, no. 11, pp. 6142–6150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Moshkani, I. I. Kuzin, F. Adewale et al., “CD23+ CD21(high) CD1d(high) B cells in inflamed lymph nodes are a locally differentiated population with increased antigen capture and activation potential,” Journal of Immunology, vol. 188, no. 12, pp. 5944–5953, 2012. View at Google Scholar
  83. J. Li, Q. Zhou, R. W. Wood et al., “CD23+/CD21hi B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice,” Arthritis Research and Therapy, vol. 13, no. 4, article R138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Li, Y. Ju, E. M. Bouta et al., “Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow,” Arthritis and Rheumatism, vol. 65, no. 1, pp. 130–138, 2013. View at Google Scholar
  85. J. S. Nosanchuk and B. Schnitzer, “Follicular hyperplasia in lymph nodes from patients with rheumatoid arthritis. A clinicopathologic study,” Cancer, vol. 24, no. 2, pp. 243–254, 1969. View at Google Scholar · View at Scopus
  86. R. F. Willkens, G. F. Roth, G. Husby, and R. C. Williams Jr., “Immunocytological studies of lymph nodes in rheumatoid arthritis and malignant lymphoma,” Annals of the Rheumatic Diseases, vol. 39, no. 2, pp. 147–151, 1980. View at Google Scholar · View at Scopus
  87. A. Manzo, R. Caporali, B. Vitolo et al., “Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography,” Rheumatology, vol. 50, no. 8, pp. 1395–1400, 2011. View at Google Scholar · View at Scopus
  88. L. G. van Baarsen, M. J. de Hair, T. H. Ramwadhdoebe et al., “The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis,” Annals of the Rheumatic Diseases, vol. 72, no. 8, pp. 1420–1424, 2013. View at Google Scholar
  89. M. J. de Hair, I. A. Zijlstra, M. J. Boumans et al., “Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool,” Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1911–1912, 2012. View at Google Scholar
  90. A. Willemze, L. A. Trouw, R. E. M. Toes, and T. W. J. Huizinga, “The influence of ACPA status and characteristics on the course of RA,” Nature Reviews Rheumatology, vol. 8, no. 3, pp. 144–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Ingegnoli, R. Castelli, and R. Gualtierotti, “Rheumatoid factors: clinical applications,” Disease Markers, vol. 35, no. 6, pp. 727–734, 2013. View at Google Scholar
  92. J.-E. Gottenberg, C. Miceli-Richard, B. Ducot, P. Goupille, B. Combe, and X. Mariette, “Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort,” Arthritis Research and Therapy, vol. 11, no. 4, article no. R114, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. J. E. Gottenberg, J. M. Dayer, C. Lukas et al., “Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort,” Annals of the Rheumatic Diseases, vol. 71, no. 7, pp. 1243–1248, 2012. View at Google Scholar
  94. A. Lahiri, P. Pochard, L. Le Pottier et al., “The complexity of the BAFF TNF-family members: implications for autoimmunity,” Journal of Autoimmunity, vol. 39, no. 3, pp. 189–198, 2012. View at Google Scholar
  95. L. Le Pottier, B. Bendaoud, Y. Renaudineau, P. Youinou, J.-O. Pers, and C. Daridon, “New ELISA for B cell-activating factor,” Clinical Chemistry, vol. 55, no. 10, pp. 1843–1851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. I. Olivieri, P. Sarzi-Puttini, S. Bugatti, F. Atzeni, S. d'Angelo, and R. Caporali, “Early treatment in early undifferentiated arthritis,” Autoimmunity Reviews, vol. 11, no. 8, pp. 589–592, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. D. L. Goldenberg and A. S. Cohen, “Synovial membrane histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease,” Medicine, vol. 57, no. 3, pp. 239–252, 1978. View at Google Scholar · View at Scopus
  98. J. D. Cañete, B. Santiago, T. Cantaert et al., “Ectopic lymphoid neogenesis in psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 6, pp. 720–726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Cantaert, J. Kolln, T. Timmer et al., “B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis,” Journal of Immunology, vol. 181, no. 1, pp. 785–794, 2008. View at Google Scholar · View at Scopus
  100. M. G. H. van de Sande, R. M. Thurlings, M. J. H. Boumans et al., “Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time?” Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 700–703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. M. di Cicco, S. Dadoun, F. Humby et al., “Synovial ectopic lymphoid-like structures are associated with diagnosis of rheumatoid arthritis, disease activity and antibody status in early arthritis patients,” Annals of the Rheumatic Diseases, vol. 72, supplement 3, p. 192, 2013. View at Google Scholar
  102. M. C. Kraan, J. J. Haringman, W. J. Post, J. Versendaal, F. C. Breedveld, and P. P. Tak, “Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis,” Rheumatology, vol. 38, no. 11, pp. 1074–1080, 1999. View at Google Scholar · View at Scopus
  103. E. Corsiero, M. Bombardieri, A. Manzo, S. Bugatti, M. Uguccioni, and C. Pitzalis, “Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases,” Immunology Letters, vol. 145, no. 1-2, pp. 62–67, 2012. View at Google Scholar
  104. C. M. Meeuwisse, M. P. van der Linden, T. A. Rullmann et al., “Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint,” Arthritis and Rheumatism, vol. 63, no. 5, pp. 1265–1273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Bugatti, A. Manzo, F. Benaglio et al., “Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs,” Arthritis Research and Therapy, vol. 14, no. 1, article R34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Rosengren, N. Wei, K. C. Kalunian, A. Kavanaugh, and D. L. Boyle, “CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis,” Rheumatology, vol. 50, no. 3, pp. 603–610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Bugatti, A. Manzo, B. Vitolo et al., “High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease,” Rheumatology, 2014. View at Publisher · View at Google Scholar
  108. S. Goya, H. Matsuoka, M. Mori et al., “Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung,” Journal of Pathology, vol. 200, no. 1, pp. 82–87, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Rangel-Moreno, D. M. Carragher, M. de La Luz Garcia-Hernandez et al., “The development of inducible bronchus-associated lymphoid tissue depends on IL-17,” Nature Immunology, vol. 12, no. 7, pp. 639–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. J. D. Cañete, R. Celis, C. Moll et al., “Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor α therapy in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 5, pp. 751–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. Y.-Q. Mo, L. Dai, D.-H. Zheng et al., “Synovial infiltration with CD79a-positive B cells, but not other B cell lineage markers, correlates with joint destruction in rheumatoid arthritis,” Journal of Rheumatology, vol. 38, no. 11, pp. 2301–2308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. K. Lanfant-Weybel, C. Michot, R. Daveau et al., “Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy—a pilot study from the VErA cohort,” Joint Bone Spine, vol. 79, no. 6, pp. 574–580, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Bugatti, A. Manzo, R. Caporali, and C. Montecucco, “Assessment of synovitis to predict bone erosions in rheumatoid arthritis,” Therapeutic Advances in Musculoskeletal Disease, vol. 4, no. 4, pp. 235–244, 2012. View at Google Scholar
  114. T. Dörner, N. Kinnman, and P. P. Tak, “Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers,” Pharmacology and Therapeutics, vol. 125, no. 3, pp. 464–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. M. J. Leandro, G. Cambridge, M. R. Ehrenstein, and J. C. W. Edwards, “Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 2, pp. 613–620, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Roll, A. Palanichamy, C. Kneitz, T. Dorner, and H.-P. Tony, “Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2377–2386, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. P. Roll, T. Dörner, and H.-P. Tony, “Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and b cell subset regeneration after repeated treatment,” Arthritis and Rheumatism, vol. 58, no. 6, pp. 1566–1575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. E. M. Vital, S. Dass, A. C. Rawstron et al., “Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment,” Arthritis and Rheumatism, vol. 62, no. 5, pp. 1273–1279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Owczarczyk, P. Lal, A. R. Abbas et al., “A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis,” Science Translational Medicine, vol. 3, no. 101, Article ID 101ra92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. J. Sellam, H. Hendel-Chavez, S. Rouanet et al., “B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis a six-month, national, multicenter, open-label study,” Arthritis and Rheumatism, vol. 63, no. 4, pp. 933–938, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. G. Ferraccioli, B. Tolusso, F. Bobbio-Pallavicini et al., “Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis,” PLoS ONE, vol. 7, no. 7, e40362 pages, 2012. View at Google Scholar
  122. J. J. Haringman, D. M. Gerlag, A. H. Zwinderman et al., “Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 834–838, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. J. Ducreux, P. Durez, C. Galant et al., “Global molecular effects of tocilizumab therapy in the rheumatoid arthritis synoviumArthritis and Rheumatism, published online first,” Arthritis & Rheumatology, vol. 66, no. 1, pp. 15–23, 2013. View at Publisher · View at Google Scholar
  124. M. H. Buch, D. L. Boyle, and S. Rosengren, “Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1220–1227, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. R. Caporali, S. Bugatti, L. Cavagna, M. Antivalle, and P. Sarzi-Puttini, “Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?” Autoimmunity Reviews, vol. 13, no. 1, pp. 49–53, 2014. View at Google Scholar
  126. K. Vos, R. M. Thurlings, C. A. Wijbrandts, D. Van Schaardenburg, D. M. Gerlag, and P. P. Tak, “Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 56, no. 3, pp. 772–778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. R. M. Thurlings, K. Vos, C. A. Wijbrandts, A. H. Zwinderman, D. M. Gerlag, and P. P. Tak, “Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response,” Annals of the Rheumatic Diseases, vol. 67, no. 7, pp. 917–925, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Kavanaugh, S. Rosengren, S. J. Lee et al., “Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 402–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. K. O. Teng, E. W. N. Levarht, R. E. M. Toes, T. W. J. Huizinga, and J. M. Van Laar, “Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 1011–1016, 2009. View at Publisher · View at Google Scholar · View at Scopus